Arizona Board of Regents, a Body Corporate

Arizona State University

Consejo Superior De Investigaciones Cientificas

Ippox Foundation

Massachusetts Institute of Technology

Universitéde Montreal

Sanofi Pasteur Inc.

Virogenetics Corporation

Centre Hospitalier Universitaire Vaudois

Aviratek Biomedical Solutions, LLC

Academisch Zikenhuis Leiden

Bertram L Jacobs

Jeffrey O Langland

Karen Kibler

James Tartaglia

Sangeetha Vijaysri

Giuseppe Pantaleo

Alexandre Harari

Rafick-Pierre Sekaly

Thierry Roger

Thierry Calandra

Mariano Esteban

Cornelius Melief

Karen Denzler

Elias El Haddad

Teresa A Brandt

Enzo Paoletti

Alexander Rich

William I Cox

Carl Wagner

Steven E Pincus

Russell Robert Gettig

John C Chaput

Scott J Goebel

William Arndt

Robert Waters

Tsafrir S Leket-mor

Lydia Meador

Elias Haddad

Brian Wellensiek

Heather Koehler

Julia Flores

Kelly Trainor

James Jancovich

Chandra Mitnik

Latha Talasela

Thomas Cahill

Guillermo Ruiz

Disclosed are compositions for generating an immune response against human immunodeficiency virus (HIV) and their methods of uses.

HIV vaccination compositions comprising vaccinia VLPS and plant-produced VLPS presenting HIV antigens

The present disclosure relates to pharmaceutical compositions comprising caffeic acid chelates, kits, and methods for using such compounds and pharmaceutical compositions.

Pharmaceutical compositions comprising caffeic acid chelates

The disclosure relates to recombinant vectors and methods for using the same. In certain embodiments, the recombinant vectors are immunogenic.

Modified immunization vectors

The present disclosure relates generally methods of preparation and use of certain botanical extracts for the treatment of viral infections.

Method for the use of botanical extracts in the treatment of viral infections

Methods utilizing vaccinia virus with mutations in E3L to infect and cause lysis of cancer cells with less than normal protein levels of RIP3 and/or DAI. Further, the disclosed vaccinia viruses with mutations in E3L cannot replicate well in cells with normal expression or upregulation of RIP3, DAI, and/or MLKL.

Oncolytic vaccinia virus mutants and using same for cancer treatment

The present disclosure relates to methods of usingextracts in inhibiting viral replication of a filovirus and in treating or preventing a filovirus infection.

Methods of using extracts of melissa officinalis against filoviruses

The present invention provides isolated polynucleotides that can serve as translation enhancing elements and their use in protein expression reagents and methods.

Genetic element that enhances protein translation

The present invention relates to vaccines having an increased level of safety comprising recombinant vaccinia viruses containing an inactivated E3L region. The invention also relates to methods for stimulating a protective immune response in an immunized host using the vaccines of the invention. The invention is based on the discovery that vaccinia virus mutants having deletions in the E3L region exhibit dramatically reduced pathogenesis while remaining highly immunogenic. In addition, the invention relates to modified recombinant vaccinia viruses engineered to express heterologous polypeptides and the use of such viruses in vaccines designed to stimulate a protective immune response against such polypeptides in a host. The invention further relates to an interferon-sensitive recombinant vaccinia virus with broad host range wherein a salamander eIF2&#x3b1; is inserted into the viral genome in place of at least a portion of the E3L gene.

Use of vaccinia virus deleted for the E3L gene as a vaccine vector

The present invention relates to methods of detecting or identifying inhibitors of a Z-DNA binding ligand to Z-DNA, methods of inhibiting the pathogenicity of an infectious agent, antiviral therapies, and compounds that inhibit complex formation between a Z-DNA binding ligand and Z-DNA.

Method of inhibiting pathogenicity of infectious agents

The present invention provides recombinant vaccinia virus having a deletion of the region encoding the C-terminal seven amino acids of the E3L gene product and comprising exogenous DNA. Compositions comprising the recombinant vaccinia virus and methods of use thereof are also provided.

Viral vectors having reduced virulence

The present invention provides methods of use of recombinant vaccinia virus from which the region encoding the N-terminal 83 or 54 amino acids of the E3L gene product has been deleted, or amino acids at positions 44 and 66 have been mutated. Compositions comprising the recombinant vaccinia virus are also provided.

Viral vectors having enhanced effectiveness with reduced virulence

The present invention provides recombinant vaccinia virus in which the E3L gene is replaced by a gene encoding an E3L homolog from the orf virus. Compositions comprising the recombinant vaccinia virus and methods of use thereof are also provided.

Recombinant vaccinia viral vectors

Growing community of inventors

Tempe, AZ, United States of America

Bertram L Jacobs